June 25, 2024
Idorsia’s treatment for chronic insomnia wins Prix Galien Suisse 2024
Idorsia said Friday its novel treatment for chronic insomnia has been awarded the Prix Galien Suisse 2024 innovation prize in…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Idorsia
October 24, 2023
Idorsia posts net revenue 9M 2023 at CHF 131 million
Idorsia has announced its financial results for the first nine months of 2023, with net revenues at CHF 29 million, of which CHF 20 million net sales with QUVIVIQ in the US and Europe (Germany, Italy, Switzerland) and CHF 9 million contract revenues.
February 25, 2022
Idorsia’s QUVIVIQ (daridorexant) Recommended for Approval in Europe as a New Treatment for Adults with Insomnia Disorder
Idorsia Ltd has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European…
May 12, 2020
Neurocrine uses option to licence rights to Idorsia’s inhibitor for treatment of rare children epilepsy
Neurocrine Biosciences has exercised its option to license the global rights to Idorsia’s ACT-709478, as it plans to initiate a Phase 2 study with this potent, selective, orally-active and brain penetrating T-type calcium channel blocker for the treatment of a rare pediatric epilepsy in the second half of 2020.
July 24, 2018
Idorsia expects non-GAAP operating expenses for 2018 to be around 390 million Swiss francs
Idorsia operated with US GAAP 155 million CHP ($156M) net loss for the first half of 2018. According to the…
June 20, 2018
Idorsia enrolls first patient into Precision phase 3 study of aprocitentan for resistant hypertension management in adults
Idorsia has enrolled the first patient into its Phase 3 study called Precision to investigate the efficacy and safety of…
June 18, 2018
Idorsia starting study to test clazosentan in certain cereblar ischemia patients
Idorsia today is initiating a Phase 3 study React to test clazosentan for the prevention of clinical deterioration due to…
May 16, 2018
Idorsia enrols first patient in study to test lucerastat as treatment for Fabry disease
Idorsia has enrolled the first patient in a Phase 3 registration study to investigate the effect of lucerastat, as an…
February 6, 2018
Idorsia six months after demerger from Actelion posts €12M net loss, announces investing in pipeline and OPEX of €336M in 2018
Idorsia Ltd has made meaningful collaboration with industry leaders in the six and a half months since the demerger from…
December 4, 2017
Idorsia welcomes $230 million milestone for Janssen’s agreement opt-in decision
Idorsia said Monday Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has exercised its option to enter…